User:J at BioNTech/sandbox/BioNTech

From Wikipedia, the free encyclopedia

BioNTech SE
Company typePublic (Societas Europaea)
Nasdaq: BNTX
(American depository receipts)
ISINUS09075V1026
IndustryBiotechnology
Founded2008; 16 years ago (2008)
Founder
Headquarters
Mainz
,
Germany
Number of locations
8 (2020)
Area served
Worldwide
Key people
ProductsBNT162b2
ServicesImmunotherapy
RevenueDecrease 121.54 million € (2019)
Total assetsIncrease 797.65 million € (2019)
Total equityIncrease 232,304,250 (2019)
Number of employees
Increase 1,323 (2019)
Websitebiontech.de

The BioNTech SE (/ˈbaɪ.ɒn.ˌtɛk/; short for Biopharmaceutical New Technologies)[1] is a Nasdaq-listed biotechnology company headquartered in Mainz, Germany,[2] focused on the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of cancer and other serious diseases. BioNTech's primary focus is on the discovery of mRNA-based drugs. These are potential candidates for individualized cancer immunotherapies, vaccines against infectious diseases, and protein replacement therapies for rare diseases. Besides, the company is active in the research of programmable cell therapies ("Engineered Cell Therapy"), novel antibodies, and small molecule immunomodulators ("small molecules") as treatment options for cancer.[3][4]

BioNTech was the first company to develop an mRNA-based human therapeutic agent for intravenous administration, to bring individualized mRNA-based cancer immunotherapy into clinical trials, and to establish its manufacturing process for such a product candidate.[4] In November 2020, the company announced that the coronavirus vaccine BNT162b2, developed in cooperation with the pharmaceutical company Pfizer, offered a vaccine efficacy of 95% to protect against COVID-19 disease.[5][6][7]

History[edit]

Foundation (2008–2013)[edit]

BioNTech was founded in 2008 based on many years of research work by Uğur Şahin, Özlem Türeci, and Christoph Huber. The company's activities focus on the development and production of technologies and drugs for individualized cancer immunotherapy.[4] Andreas and Thomas Strüngmann [Wikidata] with a starting capital of around 180 million U.S. dollars and Michael Motschmann and Helmut Jeggle were involved in the company's founding.[8][9][10] In 2009, the acquisition of EUFETS and JPT Peptide Technologies took place.[11][12][13] The same year saw Phase 1 clinical studies with MERIT (Melanoma RNA Immunotherapy; a fixed combination of cancer-specific antigens) and IVAC MUTANOME (first study with individualized neoepitopes). The initial seed financing was completed in 2009.

Expansion (2014–2018)[edit]

Between 2014 and 2018, extensive publications of the research results were made in Nature, among others.[14][15] Besides, extensive collaborations and joint development and commercialization programs were concluded with various companies and scientific institutions starting in 2015.[16][17] During this period, BioNTech filed several patent applications and developed a multi-layered strategy to protect its intellectual property in the various technology platforms and their application in the treatment of cancer and other serious diseases.

Nasdaq IPO (2019)[edit]

The focus of 2019 was the IPO on the Nasdaq. Since October 10, 2019, BioNTech has been publicly traded as American Depository Shares (ADS) on the Nasdaq Global Select Market under the ticker symbol BNTX.[18][19][20] This makes BioNTech one of eight German companies listed on the U.S. technology exchange. Before this, one of the largest European Series B financings was closed in July. BioNTech was able to generate total gross proceeds of 150 million dollars from the IPO.[21] Originally, proceeds of 250 million dollars had been expected from the IPO.[22] The consortium leaders were the investment banks J.P.Morgan, Merrill Lynch, UBS, and SVB Leerink.[23][24] With a valuation of around 3.1 billion euros based on the issue price of 15 dollars per share, BioNTech established itself in the top group of the German biotech scene based on its market capitalization.[25]

In 2019, six clinical studies were initiated using four therapeutic platforms and covering two classes of compounds. A total of ten product candidates were processed in eleven clinical studies in 2019. Also, the antibody production business of MAB Discovery,[26] antibody assets of MabVax Therapeutics,[27] and Lipocalyx were acquired in 2019.[28]

Current situation[edit]

Currently, BioNTech is working on the development of a vaccine against SARS-CoV-2.[29] When the outbreak of a new virus in China became public at the beginning of 2020, the global development project Lightspeed began as early as mid-January to develop a well-tolerated, potent vaccine against the SARS-CoV-2 virus in as short a time as possible.[3] For this purpose, BioNTech has allied with two partners, Pfizer and Fosun Pharma.[30] Studies have been successfully initiated in the USA, Europe, China,[31] Latin America, and South Africa. The first clinical trials were conducted as early as April.[32] In November 2020, BioNTech announced that the coronavirus vaccine developed together with Pfizer offered a vaccine efficacy of over 95% to protect against COVID-19 disease.[33]

Corporate structure[edit]

BioNTech is a limited liability corporation founded in Germany and based in Germany. BioNTech's shares have been publicly traded as American Depository Shares (ADS) on the Nasdaq Global Select Market since October 10, 2019. With effect from March 8, 2019, the company's name and legal form were changed from BioNTech AG to BioNTech SE. BioNTech's business is managed in two overarching business units, the Biotech Division and the External Services Division. The External Services division represents the interface through which medical devices are sold to third parties.[34]

Shareholders[edit]

The registered share capital of BioNTech amounts to €232,304,250, and it is divided into 232,304,250 bearer shares with a nominal value of one Euro. Each issued ordinary share is fully paid up.[34]

AT Impf is the largest single shareholder with a stake of over 50%. Other institutional investors associated with the Management Board and Supervisory Board members are Medine, MIG Verwaltung, and FMR. In total, companies of these board members hold almost 72% of the shares in BioNTech.[34]

Boards[edit]

Management Board[edit]

The Board of Directors of BioNTech consists of five members. Since its foundation, Uğur Şahin has been the Chairman of the Board (Chief Executive Officer).[35][36] Other members are Sean Marett (since 2012, Chief Business Officer and Chief Commercial Officer),[37][38] Sierk Poetting (since 2014, Chief Financial Officer and Chief Operating Officer),[37][39] Özlem Türeci (since 2018; Chief Medical Officer)[40][41], and Ryan Richardson (since 2020, Chief Strategy Officer).[42]

Supervisory Board[edit]

The Supervisory Board consists of four members.[43] The Chairman is Helmut Jeggle, who has held senior positions at Athos Service since 2007. He has been Chief Executive Officer and Chief Operating Officer since 2015. Before that, he held various positions at Hexal.[44][45] Other members are Ulrich Wandschneider (since 2018, from 2011 to 2016 Chief Executive Officer of the Asklepios Kliniken),[46][47] Michael Motschmann (since 2008, co-founder of the MIG administration)[48][49], and Christoph Huber (Austrian hematologist, oncologist, and immunologist with a research focus on tumor defense and stem cell transplantation. From 1990 until his retirement in 2009, he was director of the III. Medical Clinic and Polyclinic at the University Medical School of the Johannes Gutenberg University Mainz.[50][51]

Scientific Advisory Board[edit]

Since its foundation, BioNTech has been supported by a scientific advisory board headed by Rolf Zinkernagel and Hans Hengartner.[43] Rolf Zinkernagel is professor emeritus at the University of Zurich and former head of the Institute for Experimental Immunology in Zurich.[52][53] In 1996, Zinkernagel received the Nobel Prize for discovering how the immune system recognizes virus-infected cells. Hengartner is an immunologist and professor emeritus at the Swiss Federal Institute of Technology (ETH) Zurich and the University of Zurich.[4][54][55]

Locations[edit]

The headquarters of BioNTech is located in the Oberstadt district of Mainz. The company's headquarters were built on the Generalfeldzeugmeister-Kaserne barracks site, which will be completely cleared by the German Armed Forces by 2022.[56][57] BioNTech has already acquired additional land in Mainz in March 2020 in order to be able to expand.[34] The company operates several GMP-certified production facilities in Germany to manufacture mRNA therapeutics and programmable cell therapies ("Engineered Cell Therapies"). The locations are Idar-Oberstein (BioNTech Innovative Manufacturing Services), Martinsried (BioNTech Small Molecules), Neuried (BioNTech), and the fourth facility in Berlin, which offers peptide-based services and products for various areas of biomedical research (JPT Peptide Technologies).[4]

In 2019, the sites were expanded by a subsidiary in San Diego, USA (BioNTech Research & Development).[4] In 2020, Neon Therapeutics was acquired and became BioNTech US.[58] Neon was founded in 2015 by scientists, including a Nobel Prize winner, and was based on insights gained in the development of neon antigen therapies focusing on vaccines and T-cell therapeutics. The complementary skills and resources for neon antigen-based therapeutics in cancer medicine and immunology were thus combined. The merger enabled BioNTech to further expand its capabilities in the T-cell receptor field and strengthen its position in programmable T-cell therapies.[59] Neon's common stock was delisted from the stock exchange in May 2020. BioNTech US is based in Cambridge, Massachusetts, and is a fully integrated subsidiary, strengthening BioNTech's presence in the U.S.[60]

BioNTech Manufacturing Marburg

In September 2020, Novartis Vaccines and Diagnostics sold its Marburg plant to BioNTech, which has since been managed as BioNTech Manufacturing Marburg.[61] The Marburg plant is a state-of-the-art multi-platform GMP-certified production facility employing around 300 people. It is equipped for the production of recombinant proteins and cell and gene therapies. It has cell culture laboratories and production capabilities to manufacture viral vectors, with the possibility of long-term expansion.[62] The plant's acquisition enables BioNTech to expand its commercial production capacities for the manufacture of the mRNA-based COVID-19 vaccine candidate BNT162. The facility has two of BioNTech's existing GMP-certified sites that manufacture COVID-19 vaccine candidates for clinical trials and will become one of the most extensive production facilities for mRNA in Europe, along with four Pfizer sites in the U.S. and Europe.[63] Subject to regulatory approval, production of the mRNA, and LNP formulation of a COVID-19 vaccine is expected to begin in Marburg, Germany. In the plant, which employs about 300 people, annual production of 750 million vaccine doses is planned.[64][65]

The production facility in Marburg was built in 1904 by Emil von Behring for Behringwerke [Wikidata]. He developed the antidote for diphtheria and tetanus. He used the prize money he received for his Nobel Prize in Medicine in 1901 to finance the production facility.[66]

Employees[edit]

BioNTech employs over 1,300 people from more than 60 countries (as of December 2019). The proportion of women is over 56%; a quarter of the employees hold a doctorate. The average age is about 35 years. Well-known employees include Katalin Karikó and Alexandra Kemmer-Brueck.[67][68][69][70]

Key figures[edit]

Year 2017 2018 2019
Total assets (Mio. Euro) 652.99 797.65
Revenue (Mio. Euro) 69.48 150.51 121.54
Employees 710 1.026 1.323
– Research and development 511 729 973
– Production 120 168 178
– Administration 65 93 144
– Sales and Marketing 14 36 28

(Sources: Annual Reports of BioNTech SE)[71][72]

Research and technology[edit]

BioNTech's research approach is based on the view that the use of complementary, potentially synergistic mechanisms of action increases the probability of therapeutic success, reduces the risk of secondary resistance mechanisms, and also opens up a larger potential market. The key is a technology-agnostic approach to provide the most appropriate therapeutic platform or combination of platforms for each patient and disease. Bioinformatics is crucial for the production of individualized therapies. The validated patient-centered bioinformatics process enables the application of complex algorithms to patient data in the context of drug manufacturing. The bioinformatics processes are robust, scalable, and rely on handling genome data with high data processing rates. BioNTech's research is designed to enable the production of individualized on-demand immunotherapies for commercial use.

mRNA therapeutics[edit]

BioNTech is researching active ingredients based on the messenger molecule messenger RNA (mRNA) as a potential new drug class. mRNA brings genetic information to the ribosomes, the place in the cell where proteins are formed. In the ribosomes, the genetic information of mRNA is translated into corresponding proteins. First mRNA-based product candidates have already entered clinical development as cancer immunotherapeutics and vaccines against infectious diseases.[73][74][75] As a drug, the produced mRNA provides instructions to a target cell to produce a desired therapeutic protein. In cancer treatment, the produced protein is directed against target structures that are directly derived from the mutations of the cancer cells. In this way, the cancer is to be fought.[73]

BioNTech has developed several formats and formulations of mRNA to deliver genetic information to cells used for the body's protein production for therapeutic purposes.[4][73][76] BioNTech is exploring several mRNA-based therapeutic platforms for cancer immunotherapy, in particular for individualized cancer immunotherapy.

With four classes of active substances, the paradigm shift towards individualized immunotherapy is to be initiated. BioNTech's approach combines different mechanisms of action of the different drug classes to make cancer treatment more coordinated and precise than is possible with currently available therapies. The four different mRNA formats are expected to result in five different platforms for the treatment of cancer.

mRNA formats[edit]

Optimized unmodified mRNA (uRNA)

The nucleotide sequence of the mRNA determines the amino acid sequence of the protein. Also, the type of nucleosides used to produce mRNA drugs can influence the immune system's recognition of the molecule.

Nucleoside modified mRNA (modRNA) [de]

Immunogenic reactions against mRNA drugs must be avoided in applications where therapeutic proteins are produced, for example on our two platforms RiboMab and RiboCytokines.

Self-amplifying mRNA (saRNA)

Our product candidates with self-amplifying mRNA (saRNA) are based on the concept of viral replication but are neither infectious nor pathogenic. saRNA is similar to conventional mRNA: it encodes the respective protein on the one hand and a polymerase. This so-called replicase multiplies a part of the mRNA within the target cell. During self-amplification within the cell, a double-stranded RNA is formed as an intermediate stage, which is recognized by intracellular immune sensors. This enables us to achieve a robust activation of the immune system with saRNA.

Transamplifying mRNA (taRNA)

This technology is a further development of the saRNA platform. We have expanded the range of applications by separating the target mRNA to be amplified from the replicase-encoding mRNA. This makes therapeutic mRNAs more flexible since the replicase can amplify mRNA that encodes not only one protein but several different proteins.

mRNA platforms[edit]

Three of the platforms are currently in clinical trials.

  • FixVac, standard immunotherapy based on common antigens owned by BioNTech
  • iNeST, individualized neo-antigen-specific immunotherapy in collaboration with Genentech
  • Intratumoral immunotherapy in collaboration with Sanofi

Two additional platforms are also under development.

  • RiboMabs, a new class of mRNA-encoded monoclonal antibodies that aim to produce the desired antibodies directly in the patient's body using the corresponding mRNA.
  • RiboCytokines, a new class of mRNA-based therapeutics designed to directly translate cytokines in the patient. Cytokines play a central role in controlling the immune response to pathogens and malignant cells.

Engineered cell therapies[edit]

BioNTech is developing a series of new cell therapies (Engineered Cell Therapies) to modify the patient's T-cells to target cancer-specific antigens.[77][78] Research is being conducted into programmable cell therapies and an expanded patient universe.[79] Several new cell therapies are being developed in which the patient's T cells are modified to target cancer-specific antigens.[80] These include two platforms to treat solid tumors: a platform for chimeric antigen receptor T cells (CAR T cells) and a platform for T cell receptor (TCR) programs. BioNTech is investigating a CAR-T product candidate, BNT211, which targets claudin-6 (CLDN6). The CLDN6 antigen is specific for solid tumors.[4][81]

Antibodies[edit]

BioNTech is developing next-generation antibodies (checkpoint immunomodulators and targeted cancer antibodies) to modulate the patient's immune response to cancer.[4][81][82][83][84][85]

In collaboration with Genmab, BioNTech is researching bispecific antibodies that act as dual immunomodulators. For this purpose, the company applies the DuoBody technology developed by Genmab.[4][86][81] In 2019, BioNTech acquired an antibody (MVT-5873 or BNT321) with a novel mode of action from MabVax.[87]

Small molecule immunomodulators[edit]

BioNTech researches small molecules for specific immunomodulation.[88] The aim is to increase the activity of other drugs through immunomodulation.[89] In this context, the company is developing a small molecule toll-like receptor-7 (TLR7) based immunomodulator to treat solid tumors. TLR7 plays an essential role in the activation of the innate immune response. In many types of cancer, tumors are protected by an anti-inflammatory environment. This reduces the ability of the immune system to attack cancer cells. TLR7 agonists can trigger a direct cellular immune response in this case.[4] Small molecule immunomodulators or low-molecular cancer therapeutics can be used to control cancer tumors' growth, stop the formation of blood vessels in tumors, and release toxins to cancer cells. They can also be used as markers of cancer cells to make them recognizable to the immune system and destroy them. Unlike cancer therapies with larger antibody molecules, low-molecular compounds are often directed against target structures inside cells.

Research is carried out at BioNTech Small Molecules in Martinsried.[90]

Products and applications[edit]

Oncology[edit]

Cancer is caused by abnormalities known as somatic mutations. These mutations can accumulate in the genome of cells over time and lead to malignant transformation. The process of carcinogenesis involves the immune system's inability to recognize and eradicate such transformed cells.[91][92]

Immunotherapy in oncology aims to use the immune system to recognize malignant cells as "foreign" and overcome mechanisms by which cancer cells evade the immune defense. The immune system should be activated in such a way that it can limit tumor growth and destroy malignant cells. Due to their random nature, carcinogenic genetic changes lead to a set of mutations (the "mutanome") unique to each patient's tumor.[93][94] The research uses the patient-specific mutanome to develop drugs for individualized cancer immunotherapy. In this process, the treatment is tailored to the individual patient.[74] The development of cancer immunotherapies that are individually tailored to each patient is the focus of BioNTech's research activities.[4]

Technologies such as Next-Generation Sequencing (NGS for short) have undoubtedly confirmed the problematic diversity of tumors at the interindividual patient level.[95][96] Simultaneously, NGS enables fast, cost-effective, and precise high-resolution mapping of a patient's disease. The application of these groundbreaking technologies leads to a change in drug development.[97] It has the potential to significantly change the oncological treatment landscape. It is possible to incorporate comprehensive molecular mapping of tumor genes into treatment decisions and make individualized therapeutics available. This is the focus of the development of the next generation of cancer therapies.[98]

The necessary technology for such groundbreaking advances is now available in oncology. However, a radical paradigm shift in drug development is required to exploit this potential.[99]

Infectious diseases[edit]

In addition to the field of oncology, BioNTech has also implemented mRNA platforms for the development of mRNA-based vaccines against infectious disease pathogens.[100] The vaccine candidates against infectious diseases contain modified mRNA-encoding antigens specific to a target pathogen to activate T cells and B cells and instruct them to fight the pathogen.

Collaborations exist with Pfizer and the University of Pennsylvania. In August 2019, BioNTech entered into an investment agreement with the Bill & Melinda Gates Foundation to advance immunotherapies' development to prevent and/or treat HIV, tuberculosis, and up to three other infectious diseases.[101][102]

On March 17, 2020, Pfizer and BioNTech announced an agreement to develop and distribute a potential mRNA-based coronavirus vaccine to prevent COVID-19 infection.[103] To this end, the Paul Ehrlich Institute approved a Phase 1/2 clinical study for the BNT162 vaccine program on April 22, 2020.[104] By the end of April, the first group of twelve volunteers had received the first vaccination.[105]

On November 9, 2020, interim results of the pivotal study for the coronavirus vaccine were published. The reported efficacy is thus 90 percent. The risk for study participants to contract Covid-19 was more than 90 percent lower than without vaccination. Serious side effects did not occur. The approval is therefore expected to be granted in the USA in November.[106]

Rare and other diseases[edit]

In rare diseases, BioNTech has implemented platforms for the development of mRNA-based protein replacement therapies.[4] The aim is to encode and produce the required proteins directly in the patient's body using mRNA. BioNTech shares the costs and profits with Genevant Sciences.[107] Protein-based replacement therapies have been developed to treat rare diseases by administering recombinant proteins.[108] Such therapies are limited to diseases in which the missing protein function is extracellular. However, mRNA-based protein replacement therapy can potentially treat diseases with intracellular protein defects as long as the mRNA can be introduced into the affected cells.[109]

BioNTech uses several protein replacement platforms for rare diseases:

  • Concept: Therapeutic proteins encoded by mRNA and produced in the patient as an alternative to recombinant protein replacement.
  • mRNA format: Nucleoside-modified mRNA, deimmunized to avoid immune activation to translate the therapeutic protein in the cells.
  • mRNA delivery formulation: LNPs targeting the liver.

Collaborators[edit]

BioNTech has entered into several collaboration agreements with biopharmaceutical and scientific partners to expand its science and development resources. These include several agreements that allow BioNTech to maintain significant control over its development programs and participate in its products' future. The aim is to expand the potential of the technology platforms and exploit the extensive applicability of the mRNA class of drugs beyond cancer therapy to other indications. The collaborations concern oncology as well as infectious diseases and rare diseases. The biopharmaceutical partners include Genentech, Sanofi, Genmab, Genevant Sciences, Eli Lilly, Bayer, and Pfizer. Besides, BioNTech maintains research collaborations with the University of Pennsylvania ("Penn") and the TRON (Translational Oncology) Research Institute at the University Medical Center of the Johannes Gutenberg University of Mainz.[110]

Partner programs[edit]

  • Genmab: BioNTech's first collaboration was signed in May 2015 with Genmab under a licensing and collaboration agreement. The purpose of the agreement is to jointly discover, develop, and commercialize bispecific polypeptide-based antibodies. These antibodies are intended to be used against certain target structure combinations to treat cancer patients worldwide. The first product candidate is being investigated in a phase 1/2a study in solid tumors since June 2019.[111][112]
  • Eli Lilly: Together with Eli Lilly and Company, new tumor target structures and associated T-cell receptors (TCRs) have been developed since May 2015.[113][114]
  • Siemens: BioNTech has maintained a strategic partnership with Siemens since June 2015. The goal is to establish a fully automated, paperless, and digitized commercial cGMP production facility for individualized vaccines.[115][116][117]
  • Sanofi: In November 2015, BioNTech and Sanofi announced an agreement for the licensing, co-development, and commercialization of mRNA-based therapeutics for intratumoral application in solid human tumors. In March 2018, Sanofi selected the first product candidate for further development and commercialization. For this candidate, which entered clinical development in January 2019, an option to co-develop and co-promote was exercised.[118][119]
  • Bayer Animal Health: Since May 2016, BioNTech has been collaborating with Bayer Animal Health to develop novel, "first-in-class" mRNA vaccines and therapeutics specifically for use in animals.[120][121]
  • Genentech: A collaboration agreement was signed with Genentech and F. Hoffman-La Roche in September 2016. The purpose of the agreement is to jointly discover, develop, manufacture and commercialize certain pharmaceutical products containing neoepitope mRNAs for worldwide use. These include our development candidates for individualized neoantigen-specific immunotherapy (iNeST).[122][123]
  • Genevant: In July 2018, a collaboration was signed with Genevant to develop mRNA-based therapeutics for rare diseases.[124][125]
  • Pfizer: In collaboration with Pfizer, mRNA-based vaccines are being developed for Influenza prevention. The agreement was announced in August 2018.[126][127]
  • Bill & Melinda Gates Foundation (BMGF): In August 2019, a research and development agreement was signed with the BMGF in HIV and tuberculosis and up to three other infectious diseases. The foundation's commitment can be up to USD 100 million. The funds will be used to identify and preclinically develop vaccine and immunotherapy candidates for the prevention of HIV and Tuberculosis infections as well as for sustained antiretroviral therapy-free remission of HIV disease.[128][129][130]
  • InstaDeep: In November 2020, BioNTech announced a strategic partnership with the British company, including creating an A.I. Innovation Lab to develop new immunotherapies.[131]

Science and medicine[edit]

For clinical trials, BioNTech cooperates with a large number of universities and medical centers in Europe and the USA.

  • Translational Oncology at the University Medical Center of the Johannes Gutenberg University of Mainz (TRON)' is a biopharmaceutical research institute at the University of Mainz that develops new diagnostics and drugs for the treatment of cancer and other serious diseases.[132][133]
  • Ci3 is a non-profit association with more than 500 scientists, which networks players from science, hospitals, and relevant authorities. The goal is to realize groundbreaking individual immune therapies.[134][135][136]
  • German Center for Infection Research [Wikidata] (DZIF): The DZIF aims to close the gap that has existed until now between the discovery of new treatment approaches, preclinical and clinical research.[137][138]
  • Neoantigen Initiative "Tumor Neoantigen Selection Alliance" (TESLA) of the Parker Institute for Cancer Immunotherapy. This non-profit organization brings together researchers from the fields of science, non-profit organizations, pharmacy, and biotechnology to collaborate in the treatment of the most deadly cancers.[139][140]
  • University of Pennsylvania: A research collaboration with the University has been in place since October 2018. BioNTech has the exclusive option to develop and commercialize mRNA immunotherapies to treat up to ten indications of infectious diseases.[141][142]

Patents[edit]

In the area of patents, BioNTech has developed a multi-layered strategy to protect intellectual property rights for the various technology platforms and their application in the treatment of cancer and other serious diseases. A key focus of the intellectual property strategy is protecting the platforms and product candidates developed by BioNTech that are currently in development. In this context, the emphasis is also on protecting intellectual property for assets that may be used in future development programs and/or that may be of interest to employees or otherwise prove valuable in this field.[143]

BioNTech has more than 200 patent families in total ownership, including in-licensed patent portfolios and more than 100 patent families owned exclusively or jointly by BioNTech.[144] All patents cover at least one occupation in the E.U. or the U.S.; several are pending in several countries or have been granted in several jurisdictions.[145]

BioNTech has held patents on mRNA for years.[146] mRNA is successfully used in medical and immunological applications but is inherently very short-lived. Externally introduced, injected mRNA is normally degraded before it could start the protein production for the immune response with the pathogen's construction plan. For this purpose, a method was discovered and patented years ago to stabilize injected mRNA very well. This was discovered and patented by a Polish team led by Jacek Jemielity, who had already entered into a partnership with BioNTech in 2008 to further develop the process.[147][148] BioNTech has already licensed the stabilized mRNA technology to major pharmaceutical companies, including the French company Sanofi (in 2015) and Genentech (2016). Moderna, GSK - and the two German companies BioNTech and CureVac own almost half of all patent applications for mRNA vaccines.[149]

Selected patents
  • US patent 9476055, Sahin, Ugur; Holtkamp, Silke; Tureci, Ozlem; Kreiter, Sebastian, "Modification of RNA, Producing an Increased Transport Stability and Translation Efficiency", published 2010-05-27, assigned to BioNTech 
  • US patent 9295717, Sahin, Ugur; Kuhn, Andreas; Darzynkiewicz, Edward; Jemielity, Jacek; Kowalska, Joanna, "Vaccine Composition Comprising 5'-Cap Modified RNA", published 2012-08-02, assigned to BioNTech; TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-universitat Mainz; Uniwersytet Warszawski 
  • US patent 14388192, Sahin, Ugur; Haas, Heinrich; Kreiter, Sebastian; Diken, Mustafa; Fritz, Daniel; Meng, Martin; Kranz, Lena Mareen; Reuter, Kerstin, "RNA Formulation for Immunotherapy", published 2015-03-26, assigned to BioNTech RNA Pharmaceuticals and TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-universitat Mainz 
  • US patent 14647577, Sahin, Ugur; Paret, Claudia; Vormbrock, Kirsten; Bender, Christian; Diekmann, Jan, "Individualized Vaccines for Cancer", published 2016-03-03, assigned to BioNTech RNA Pharmaceuticals and TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-universitat Mainz 
  • US patent 10106800, Sahin, Ugur; Holtkamp, Silke; Tureci, Ozlem; Kreiter, Sebastian, "Modification of RNA, Producing an Increased Transcript Stability and Translation Efficiency", published 2017-01-12, assigned to BioNTech 

Publications[edit]

mRNA therapeutics[edit]

  • Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Tureci O and Sahin U; et al. (2010), "Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.", Cancer Res, vol. 70, no. 22, pp. 9031–9040, PMID 21045153{{citation}}: CS1 maint: multiple names: authors list (link)
  • Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C (2012), "Exploiting the mutanome for tumor vaccination.", Cancer Res, vol. 72, no. 5, pp. 1081–1091, PMID 22237626{{citation}}: CS1 maint: multiple names: authors list (link)
  • Kowalska J, Wypijewska del Nogal A, Darzynkiewicz ZM, Buck J, Nicola C, Kuhn AN, Lukaszewicz M, Zuberek J, Strenkowska M, Ziemniak M (2014), "Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes.", Nucleic Acids Res, vol. 42, no. 16, pp. 10245–10264, PMID 25150148{{citation}}: CS1 maint: multiple names: authors list (link)
  • Sahin U, Kariko K and Tureci O (2014), "mRNA-based therapeutics–developing a new class of drugs.", Nat Rev Drug Discov, vol. 13, no. 10, pp. 759–780, PMID 25150148
  • Castle JC, Loewer M, Boegel S, de Graaf J, Bender C, Tadmor AD, Boisguerin V, Bukur T, Sorn P, Paret C. (2014), "Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.", BMC Genomics, vol. 15, no. 190, PMID 24621249{{citation}}: CS1 maint: multiple names: authors list (link)
  • Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, Boegel S, Schrors B, Vascotto F, Castle JC (2015), "Mutant MHC class II epitopes drive therapeutic immune responses to cancer.", Nature, vol. 520, no. 7549, pp. 692–696, PMID 25901682{{citation}}: CS1 maint: multiple names: authors list (link)
  • Poleganov MA, Eminli S, Beissert T, Herz S, Moon JI, Goldmann J, Beyer A, Heck R, Burkhart I, Barea Roldan D (2015), "Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion.", Hum Gene Ther, no. 11, pp. 751–766, PMID 26381596{{citation}}: CS1 maint: multiple names: authors list (link)
  • Grabbe S, Haas H, Diken M, Kranz LM, Langguth P, Sahin U. (2016), "Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.", Nanomedicine, no. 534, pp. 2723–2734, PMID 27700619{{citation}}: CS1 maint: multiple names: authors list (link)
  • Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö. (2017), "Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.", Nature, no. 547, pp. 222–226, PMID 28678784{{citation}}: CS1 maint: multiple names: authors list (link)
  • Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, Sahin U. (2017), "Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.", Nature Medicine, pp. 815–817, doi:10.1038/nm.4356{{citation}}: CS1 maint: multiple names: authors list (link)
  • Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D. (2017), "Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.", Nature, no. 543, pp. 248–251, PMID 28151488{{citation}}: CS1 maint: multiple names: authors list (link)

Engineered cell therapies[edit]

  • Simon P, Omokoko TA, Breitkreuz A, Hebich L, Kreiter S, Attig S, Konur A, Britten CM, Paret C, Dhaene K (2014), "Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.", Cancer Immunol Res, vol. 2, no. 12, pp. 1230–1244, PMID 25245536{{citation}}: CS1 maint: multiple names: authors list (link)
  • Omokoko T, Simon P, Tureci O and Sahin U (2015), "Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies.", Oncoimmunology, vol. 4, no. 7, PMID 26140230{{citation}}: CS1 maint: multiple names: authors list (link)

Antibodies[edit]

Microbodies
  • Krause S, Schmoldt HU, Wentzel A, Ballmaier M, Friedrich K, Kolmar H. (2007), "Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists.", FEBS J, pp. 86–95, PMID 17147697{{citation}}: CS1 maint: multiple names: authors list (link)
  • Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Wentzel A, Frauendorf H, Sommerhoff CP, Diederichsen U, Kolmar H. (2008), "Head-to-tail cyclized cystine-knot peptides by a combined recombinant and chemical route of synthesis.", Chembiochem, vol. 9, no. 1, PMID 18058774{{citation}}: CS1 maint: multiple names: authors list (link)
  • Sommerhoff CP, Avrutina O, Schmoldt HU, Gabrijelcic-Geiger D, Diederichsen U, Kolmar H (2010), "Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase beta.", J Mol Biol, vol. 8, no. 395, doi:10.1016/j.jmb.2009.10.028, PMID 19852971{{citation}}: CS1 maint: multiple names: authors list (link)
Bispecific antibodies
  • Christiane R Stadler, Hayat Bähr-Mahmud, Laura M Plum, Kathrin Schmoldt, Anne C Kölsch, Özlem Türeci & Ugur Sahin (2015), "Characterization of the First-in-Class T-Cell Engaging Bispecific Single-Chain Antibody for Targeted Immunotherapy of Solid Tumors Expressing the Oncofetal Protein Claudin 6.", OncoImmunology, doi:10.1080/2162402X.2015.1091555{{citation}}: CS1 maint: multiple names: authors list (link)
  • Stadler CR, Bähr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Karikó K, Türeci Ö, Sahin U. (2017), "Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.", Nature Medicine, vol. 23, no. 7, pp. 815–817, doi:10.1038/nm.4356, PMID 28604701{{citation}}: CS1 maint: multiple names: authors list (link)
Virus-like-particles
  • Klamp T, Schumacher J, Huber G, Kuhne C, Meissner U, Selmi A, Hiller T, Kreiter S, Markl J, Tureci O (2011), "Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases.", Cancer Res, vol. 71, no. 2, pp. 516–527, PMID 21224362{{citation}}: CS1 maint: multiple names: authors list (link)
  • Schumacher J, Bacic T, Staritzbichler R, Daneschdar M, Klamp T, Arnold P, Jägle S, Türeci Ö, Markl J and Sahin U (2018), "Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide.", Journal of Nanobiotechnology, vol. 16, no. 1, doi:10.1186/s12951-018-0363-0, PMID 29653575{{citation}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)

Small molecule immunomodulators[edit]

  • Vascotto F, Petschenka J, Walzer KC, Vormehr M, Brkic M, Strobl S, Rösemann R, Diken M, Kreiter S, Türeci Ö, Sahin U (2019), "Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response.", Oncoimmunology, vol. 8, no. 7, PMID 31143525{{citation}}: CS1 maint: multiple names: authors list (link)

Further reading[edit]

Notes and references[edit]

  1. ^ "Mainzer Unternehmen BioNTech testet Corona-Impfstoff.", SWR aktuell (in German), April 23, 2020, retrieved November 12, 2020
  2. ^ René Höltschi (November 9, 2020), "Mainzer Hoffnungsträger in der Corona-Krise: Wer ist BioNTech?", Neue Zürcher Zeitung (in German), retrieved November 12, 2020
  3. ^ a b Our Vision, BioNTech SE, retrieved October 13, 2020
  4. ^ a b c d e f g h i j k l m BioNTech SE (September 9, 2019), Form F-1, U.S. Securities and Exchange Commission, retrieved September 23, 2020
  5. ^ "Corona: BioNTech-Impfstoff erreicht Wirksamkeit von 95 Prozent", Die Welt (in German), November 18, 2020, retrieved November 27, 2020
  6. ^ Eva Müller, Lukas Heiny (November 9, 2020), "Projekt „Lightspeed" – so lief die Suche nach BioNTechs Impfstoff.", Manager Magazin (in German), retrieved November 12, 2020
  7. ^ Phase-II/III-Studie des RNA-Impfstoffkandidaten BNT162b2 des Unternehmens BioNTech in Deutschland genehmigt. (in German), Paul-Ehrlich-Institut, September 9, 2020, retrieved November 12, 2020
  8. ^ Jürgen Salz (June 18, 2020), "BioNTech-Investor Strüngmann: Der Pharma-David", WirtschaftsWoche (in German), retrieved November 11, 2020
  9. ^ Der Hoffnungsträger hinter den Visionen (in German), May 6, 2020, retrieved November 11, 2020
  10. ^ Sebastian Balzter, "Impfen gegen Corona: „Das wird noch einige Jahre dauern, fürchte ich".", Frankfurter Allgemeine Zeitung (in German), ISSN 0174-4909, retrieved November 11, 2020
  11. ^ Eufets Becomes BioNTech Innovative Manufacturing Services, BioNTech IMFS, September 18, 2017, retrieved November 11, 2020
  12. ^ "JPT Peptide Technologies veröffentlicht den Human Proteome Peptide Catalog.", Pharmazeutische Zeitung (in German), April 10, 2018, retrieved November 11, 2020
  13. ^ Wista-Management (April 24, 2020), Peptide von JPT machen Wirkung eines COVID-19-Impfstoffs sichtbar. (in German), retrieved November 11, 2020
  14. ^ Lena M. Kranz, Mustafa Diken, Heinrich Haas, Sebastian Kreiter, Carmen Loquai (June 16, 2016), "Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy", Nature, vol. 534, no. 7607, pp. 396–401, doi:10.1038/nature18300, ISSN 1476-4687, PMID 27281205, retrieved November 11, 2020{{citation}}: CS1 maint: multiple names: authors list (link)
  15. ^ Lena M. Kranz, Mustafa Diken, Heinrich Haas, Sebastian Kreiter, Carmen Loquai (2016-06), "Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy", Nature, vol. 534, no. 7607, pp. 396–401, doi:10.1038/nature18300, ISSN 1476-4687, retrieved 2020-11-11 {{citation}}: Check date values in: |date= (help)CS1 maint: multiple names: authors list (link)
  16. ^ "Pfizer setzt BioNTech auf Grippevakzine an", Transkript (in German), Bicom, retrieved November 11, 2020
  17. ^ "BioNTech schließt weltweite strategische Zusammenarbeit mit Genentech", GoingPublic (in German), September 22, 2016, retrieved November 11, 2020
  18. ^ BioNTech SE, Nasdaq, retrieved November 12, 2020
  19. ^ BioNTech: Deutsches IPO an der Nasdaq (in German), ARD, retrieved November 11, 2020
  20. ^ Ilka Kopplin (October 10, 2019), "Biotechnologie: BioNTech nimmt weniger Geld ein als erwartet.", Frankfurter Allgemeine Zeitung (in German), ISSN 0174-4909, retrieved November 11, 2020
  21. ^ Siegfried Hofmann (October 10, 2019), "Biotech: Der Börsengang der Mainzer BioNTech bringt die Rangordnung der deutschen Biotech-Branche durcheinander.", Handelsblatt (in German), retrieved November 11, 2020
  22. ^ "BioNTech-IPO fällt kleiner aus – 20 Prozent geringeres Volumen - Mainzer Unternehmen startet an der Nasdaq.", Börsen-Zeitung (in German), p. 12, October 11, 2019
  23. ^ "BioNTech konkretisiert Nasdaq-Listing", Ärzte-Zeitung (in German), September 26, 2019, retrieved November 12, 2020
  24. ^ "BioNTech kündigt weitere Schritte für geplanten Börsengang an.", Wallstreet Online (in German), September 24, 2019, retrieved November 12, 2020
  25. ^ "BioNTech-Chef Sahin erklärt, was sich durch den Börsengang ändert", Handelsblatt (in German), October 13, 2019, retrieved November 27, 2020
  26. ^ "BioNTech kauft MAB Discoverys Antikörper-Einheit", BioM Cluster Development (in German), retrieved November 11, 2020
  27. ^ BioNtech aquires antibody assets from MabVax Therapeutics, Biocom, May 9, 2019, retrieved November 11, 2020
  28. ^ Johannes Vetter, Volksstimme Magdeburg (November 11, 2020), "Mit doppelter Kraft gegen das Coronavirus", Volksstimme (in German), retrieved November 11, 2020
  29. ^ Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study (Press Release), BioNTech SE, September 11, 2020, retrieved November 11, 2020
  30. ^ "Coronavirus: Commission approves contract with BioNTech-Pfizer alliance to ensure access to a potential vaccine", Press corner of the European Commission, European Commission, November 11, 2020, retrieved November 29, 2020.
  31. ^ "BioNTech mit COVID-19 News aus China – Aktie leicht unter Druck", 4investors (in German), November 25, 2020, retrieved November 26, 2020
  32. ^ "Erste Studie zu Corona-Impfstoff in Deutschland läuft an.", Hessenschau (in German), April 22, 2020, retrieved November 11, 2020
  33. ^ "Letzte Analyse vor der Zulassung bestätigt BioNTech-Impfstoff Wirksamkeit von 95 Prozent.", Welt (in German), November 18, 2020, retrieved November 27, 2020
  34. ^ a b c d BioNTech SE (March 31, 2020), Form 20-F, U.S. Securities and Exchange Commission, retrieved November 10, 2020
  35. ^ Fanny Jimenez (November 10, 2020), BioNTech-CEO Ugur Sahin über seinen Corona-Impfstoff: „Wir haben unser Projekt ‚Lightspeed‘ genannt, um klarzumachen: Wir vergeuden keine Zeit.“ (in German), retrieved November 11, 2020
  36. ^ Jan Siegrist (November 10, 2020), Coronavirus: Dieses Ehepaar steckt hinter Impfstoff-Durchbruch (in German), Nau Media, retrieved November 11, 2020
  37. ^ a b Ingo Malcher (June 3, 2020), "BioNTech: Im Team gegen Corona", Die Zeit, retrieved November 27, 2020
  38. ^ Helen Albert (December 18, 2019), How BioNTech Navigates the Biotech Fundraising Maze, retrieved November 11, 2020
  39. ^ "Sierk Poetting, CFO, BioNTech SE", Topio Networks, retrieved November 11, 2020
  40. ^ Lastruperin ist Corona-Hoffnung: BioNTech-Gründerin Türeci (in German), NDR, retrieved November 11, 2020
  41. ^ Finn Mayer-Kuckuk (November 10, 2020), "Porträt über die BioNTech-Chefs: Das Forscherpaar", Die Tageszeitung (taz) (in German), ISSN 0931-9085, retrieved November 11, 2020
  42. ^ "BioNTech beruft Ryan Richardson als Chief Strategy Officer in den Vorstand", Labo (in German), retrieved November 11, 2020
  43. ^ a b Führungsteam, BioNTech SE, retrieved November 11, 2020
  44. ^ Sebastian Balzter, "Impfen gegen Corona: „Das wird noch einige Jahre dauern, fürchte ich".", Frankfurter Allgemeine Zeitung (in German), ISSN 0174-4909, retrieved November 11, 2020
  45. ^ Andreas Geldner (February 6, 2020), "Risikokapital für Biotechnologie: Ohne Geduld und Idealismus geht es nicht.", Stuttgarter Zeitung (in German), retrieved November 11, 2020
  46. ^ "BioNTech Announces Corporate Form Transition from AG to SE; Welcomes Ryan Richardson as Senior Vice President Corporate Development and Strategy and Appoints Dr. Ulrich Wandschneider as Member of Supervisory Board.", Business Wire, January 4, 2019, retrieved November 11, 2020
  47. ^ Dr. Ulrich Wandschneider (in German), Gesundheitswirtschaftskongress 2019, retrieved November 11, 2020
  48. ^ Der Börsengang in den USA hat BioNTech auf das internationale Parkett gehoben (in German), MIG Fonds, March 24, 2020, retrieved November 12, 2020
  49. ^ Zielunternehmen der MIG Fonds (hier S. 20: BioNTech AG) (PDF) (in German), Heiter Investment, retrieved November 12, 2020
  50. ^ "Christoph Huber: Pionier der Krebsforschung – Personalien", Deutsches Ärzteblatt (in German), July 7, 2014, retrieved November 11, 2020
  51. ^ Immunologe Christoph Huber mit Bundesverdienstkreuz ausgezeichnet. (in German), Universitätsmedizin Mainz, retrieved November 11, 2020
  52. ^ Stefan Stöcklin (March 26, 2020), RNA-Technologie: Corona-Vakzin im Schnelltempo (in German), Universität Zürich, retrieved November 11, 2020
  53. ^ Manfred Lindinger, "Peter Doherty zum Achtzigsten: Entschlüsselte Immunabwehr", Frankfurter Allgemeine Zeitung (in German), ISSN 0174-4909, retrieved November 11, 2020
  54. ^ "Hans Hengartner", Company House (in German), retrieved November 11, 2020
  55. ^ Curriculum Vitae Professor Dr. Hans Hengartner (PDF) (in German), Leopoldina – Nationale Akademie der Wissenschaften, retrieved November 27, 2020
  56. ^ IHK: Planungssicherheit für BioNTech schaffen. Günster: Unternehmen der Spitzenforschung am Standort Mainz halten. (in German), IHK Rheinhessen, retrieved November 12, 2020
  57. ^ "Bebauung der GFZ-Kaserne: Mehr Platz für BioNTech?", Allgemeine Zeitung Mainz (in German), VRM, May 25, 2020, retrieved November 12, 2020
  58. ^ BioNTech SE (May 6, 2020), "BioNTech schließt Übernahme von Neon Therapeutics ab.", Global News Wire (in German), retrieved November 11, 2020
  59. ^ "BioNTech übernimmt Neon um globale Führungsposition in T-Zell-Therapien zu stärken", finanzen.net (in German), January 16, 2020, retrieved November 10, 2020
  60. ^ "BioNTech übernimmt Neon um globale Führungsposition in T-Zell-Therapien zu stärken.", finanznachrichten.de (in German), BioNTech SE; Neon Therapeutics, Inc., retrieved November 11, 2020
  61. ^ Novartis Produktionsstandort in Marburg geht an Biotechnologie-Unternehmen (in German), Novartis Deutschland, September 17, 2020, retrieved November 11, 2020
  62. ^ cm/dpa (September 18, 2020), "BioNTech will Novartis-Werk für Impfstoffproduktion übernehmen", Deutsche Apotheker Zeitung (in German), retrieved November 11, 2020
  63. ^ Patrick Eickemeier (September 17, 2020), "BioNTech produziert Covid-19-Impfstoff in Marburg", Der Tagesspiegel (in German), retrieved November 11, 2020
  64. ^ "Coronavirus: BioNTech übernimmt Novartis-Werk in Marburg für die Impfstoffproduktion", Der Spiegel (in German), September 17, 2020, retrieved September 18, 2020
  65. ^ "BioNTech übernimmt 300 Marburger Mitarbeiter.", Gießener Anzeiger (in German), September 20, 2020, retrieved November 11, 2020
  66. ^ Geschichte des Instituts für experimentelle Therapie Marburg (in German), Emil-von-Behring-Bibliothek der Universität Marburg, Arbeitsstelle für Geschichte der Medizin, retrieved November 12, 2020
  67. ^ "Katalin Karikó", 8th International mRNA Health Conference, retrieved November 11, 2020
  68. ^ "Katalin Karikó", Topio Networks, retrieved November 11, 2020
  69. ^ "Alexandra Kemmer-Brueck's research while affiliated with BioNTech AG and other places", ResearchGate, retrieved November 20, 2020
  70. ^ Patricia Silva, PhD (April 30, 2015), "BioNTech Collaborative Study Reveals a Potential New Strategy for Personalized Cancer Immunotherapy", Melanoma News Today, retrieved November 11, 2020
  71. ^ "BioNTech Bilanz GuV - Kennzahlen - Umsatz - Gewinn", finanzen.net (in German), retrieved November 11, 2020
  72. ^ Sascha Huber, "BioNTech: US-IPO verläuft ein wenig enttäuschend.", sharedeals.de (in German), retrieved November 11, 2020
  73. ^ a b c Sahin, U; Karikó, K; Türeci, Ö (2014), "mRNA-based therapeutics – developing a new class of drugs", Nat Rev Drug Discov, 13 (10): 759–780, doi:10.1038/nrd4278, PMID 25233993
  74. ^ a b Sahin, U; Derhovanessian, E; Miller, M; Kloke, BP; Simon, P; Löwer, M; Bukur, V; Tadmor, AD; Luxemburger, U; Schrörs, B; Omokoko, T; Vormehr, M; Albrecht, C; Paruzynski, A; Kuhn, AN; Buck, J; Heesch, S; Schreeb, KH; Müller, F; Ortseifer, I; Vogler, I; Godehardt, E; Attig, S; Rae, R; Breitkreuz, A; Tolliver, C; Suchan, M; Martic, G; Hohberger, A; Sorn, P (2017), "Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer", Nature, 547 (7662): 222–226, doi:10.1038/nature23003, PMID 28678784
  75. ^ Sahin, U; Türeci, Ö (2018), "Personalized vaccines for cancer immunotherapy", Science, 359 (6382): 1355–1360, doi:10.1126/science.aar7112, PMID 29567706
  76. ^ Kreiter, S; Selmi, A; Diken, M; Koslowski, M; Britten, CM; Huber, C; Türeci, Ö; Sahin, U (2010), "Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity", Cancer Res, 70 (22): 9031–9040, doi:10.1158/0008-5472.CAN-10-0699, PMID 21045153
  77. ^ Simon, P; Omokoko, TA; Breitkreuz, A; Hebich, L; Kreiter, S; Attig, S; Konur, A; Britten, CM; Paret, C; Dhaene, K; Türeci, Ö; Sahin, U (2014), "Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes", Cancer Immunol Res, 2 (12): 1230–1244, doi:10.1158/2326-6066.CIR-14-0108, PMID 25245536
  78. ^ Omokoko, T; Simon, P; Türeci, Ö; Sahin, U (2015), "Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies", Oncoimmunology, 4 (7): e1005523, doi:10.1080/2162402X.2015.1005523, PMID 26140230
  79. ^ Maike Telgheder (September 17, 2020), "Biotechunternehmen: Corona-Pionier BioNTech forscht an vielen Wirkstoffen gegen Krebs", Handelsblatt (in German), retrieved November 11, 2020
  80. ^ "Biotechfirma BioNTech entwickelt hauptsächlich Immuntherapie zur Krebsbehandlung", Yahoo News (in German), retrieved November 11, 2020
  81. ^ a b c Stadler, CR; Bähr-Mahmud, H; Plum, LM; Schmoldt, K; Kölsch, AC; Türeci, Ö; Sahin, U (2015), "Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6", Oncoimmunology, 5 (3): e1091555, doi:10.1080/2162402X.2015.1091555, PMID 27141353
  82. ^ Sommerhoff, CP; Avrutina, O; Schmoldt, HU; Gabrijelcic-Geiger, D; Diederichsen, U; Kolmar, H (2010), "Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase beta", J Mol Biol, 395 (1): 167–175, doi:10.1016/j.jmb.2009.10.028, PMID 19852971
  83. ^ Avrutina, O; Schmoldt, HU; Gabrijelcic-Geiger, D; Wentzel, A; Frauendorf, H; Sommerhoff, CP; Diederichsen, U; Kolmar, H (2008), "Head-to-tail cyclized cystine-knot peptides by a combined recombinant and chemical route of synthesis", Chembiochem, 9 (1): 33–37, doi:10.1002/cbic.200700452, PMID 18058774
  84. ^ Krause, S; Schmoldt, HU; Wentzel, A; Ballmaier, M; Friedrich, K; Kolmar, H (2007), "Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists", FEBS J, 274 (1): 86–95, doi:10.1111/j.1742-4658.2006.05567.x, PMID 17147697
  85. ^ Klamp, T; Schumacher, J; Huber, G; Kuhne, C; Meissner, U; Selmi, A; Hiller, T; Kreiter, S; Markl, J; Türeci, Ö; Sahin, U (2011), "Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases", Cancer Res, 71 (2): 516–527, doi:10.1158/0008-5472.CAN-10-2292, PMID 21224362
  86. ^ Stadler, CR; Bähr-Mahmud, H; Celik, L; Hebich, B; Roth, AS; Roth, RP; Karikó, K; Türeci, Ö; Sahin, U (2017), "Elimination of large tumors in mice by mRNA-encoded bispecific antibodies", Nat Med, 23 (7): 815–817, doi:10.1038/nm.4356, PMID 28604701
  87. ^ BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio (PDF), BioNTech SE, May 9, 2019, retrieved November 21, 2020
  88. ^ BioNTech erhält BMBF-Förderung von bis zu 375 Millionen Euro für COVID-19-Impfstoffprogramm BNT162 (in German), BioNTech SE, September 15, 2020, retrieved November 11, 2020
  89. ^ Vascotto, F; Petschenka, J; Walzer, KC; Vormehr, M; Brkic, M; Strobl, S; Rösemann, R; Diken, M; Kreiter, S; Türeci, Ö; Sahin, U (2019), "Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response", Oncoimmunology, 8 (7): 1601480, doi:10.1080/2162402X.2019.1601480, PMID 31143525
  90. ^ 4SC konzentriert sich auf die klinische Entwicklung von epigenetischen Substanzen und veräußert den operativen Teil seiner Discovery-Sparte. (in German), retrieved November 11, 2020
  91. ^ Vormehr, M; Diken, M; Boegel, S; Kreiter, S; Türeci, Ö; Sahin, U (2016), "Mutanome directed cancer immunotherapy", Curr Opin Immunol, 39: 14–22, doi:10.1016/j.coi.2015.12.001, PMID 26716729
  92. ^ Stratton, MR; Campbell, PJ; Futreal, PA (2009), "The cancer genome", Nature, 458 (7239): 719–724, doi:10.1038/nature07943, PMID 19360079
  93. ^ Stratton, MR (2011), "Exploring the genomes of cancer cells: progress and promise", Science, 331 (6024): 1553–1558, doi:10.1126/science.1204040, PMID 21436442
  94. ^ Kreiter, S; Castle, JC; Türeci, Ö; Sahin, U (2012), "Targeting the tumor mutanome for personalized vaccination therapy", Oncoimmunology, 1 (5): 768–769, doi:10.4161/onci.19727, PMID 22934277
  95. ^ Transferinitiative RLP | Technologien made in Rheinland-Pfalz | Who is Who | Sequenzierung & Datenanalyse (PDF) (in German), retrieved November 22, 2020
  96. ^ "Neuer Therapieansatz: BioNTech entwickelt individualisierte Krebsmittel.", Pharmazeutische Zeitung (in German), retrieved November 11, 2020
  97. ^ "Wette auf die Zukunft – Biotech-Branche mit nur wenigen Leuchttürmen", t3n.de (in German), retrieved November 11, 2020
  98. ^ Marion Schlegel, "Deutscher Biotech-Senkrecht-Starter BioNTech nicht zu bremsen: „Sie können uns mit Tesla vergleichen".", Der Aktionär (in German), retrieved November 11, 2020
  99. ^ "Individualized cancer medicine". BioNTech. Retrieved November 29, 2020.
  100. ^ Thorsten Winter, "Krebs und Infektionen: Neuartige Impfstoffe als Ziel", Frankfurter Allgemeine Zeitung (in German), ISSN 0174-4909, retrieved November 11, 2020
  101. ^ "The Gates Foundation sees BioNTech potential to 'dramatically reduce global HIV and tuberculosis'". The Pharma Letter. September 5, 2019. Retrieved November 29, 2020.
  102. ^ BioNTech, The Gates Foundation, retrieved November 11, 2020
  103. ^ Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine, BioNTech SE, retrieved July 28, 2020
  104. ^ BioNTech und Pfizer geben Genehmigung des Paul-Ehrlich-Instituts für erste klinische Studie von COVID-19-Impfstoffkandidaten bekannt. (in German), BioNTech SE, April 22, 2020, retrieved April 22, 2020
  105. ^ BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany, BioNTech SE, April 29, 2020, retrieved April 29, 2020
  106. ^ "Corona-Impfstoff: BioNTech meldet 90-prozentige Wirksamkeit von Impfstoff.", Die Zeit (in German), November 9, 2020, retrieved November 9, 2020
  107. ^ MarketScreener, "BioNTech und Genevant Sciences vereinbaren strategische Partnerschaft mit mRNA-Fokus für seltene Erkrankungen", MarketScreener (in German), retrieved November 11, 2020
  108. ^ Strategische Partnerschaft mit mRNA-Fokus für seltene Erkrankungen (in German), retrieved November 11, 2020
  109. ^ BioNTech veröffentlicht Ergebnisse des gesamten Geschäftsjahres 2019 sowie Informationen zur Geschäftsentwicklung (in German), BioNTech SE, retrieved November 11, 2020
  110. ^ BioNTech Kooperationspartner (in German), retrieved November 11, 2020
  111. ^ GoingPublic (May 22, 2015), "BioNTech schließt Kooperation mit Genmab", GoingPublic (in German), retrieved November 11, 2020
  112. ^ "Freshfields Bruckhaus Deringer: BioNTech startet Kooperationen in der Krebsforschung", Legal Tribune Online (in German), retrieved November 11, 2020
  113. ^ JUVE- www.juve.de, Krebstherapie: Freshfields und Honert beraten BioNTech bei Deal mit Eli Lilly « JUVE (in German), retrieved November 11, 2020
  114. ^ "Mainz: BioNTech AG wächst rasant weiter – Millionenschwere Kooperation mit Pfizer", Allgemeine Zeitung Mainz (in German), VRM, August 17, 2018, retrieved November 11, 2020
  115. ^ Austria Presse Agentur (APA), Siemens und BioNTech kooperieren bei der Produktion personalisierter Krebsimpfstoffe (in German), retrieved November 11, 2020
  116. ^ Siemens und BioNTech vereinbaren strategische Zusammenarbeit (in German), retrieved November 11, 2020
  117. ^ Ein eigenes Arzneimittel für jeden Patienten (in German), Siemens Global, retrieved November 11, 2020
  118. ^ Sanofi intensiviert Kooperation mit BioNTech (in German), retrieved November 11, 2020
  119. ^ "Sanofi investiert in BioNTech: Weiterer Pharmariese steigt bei deutschem Biotech-Star ein.", Handelsblatt (in German), retrieved November 11, 2020
  120. ^ "BioNTech wählt Bayer als Partner", Transkript (in German), Biocom, retrieved November 11, 2020
  121. ^ "Tiermedizin: Bayer und BioNTech entwickeln Impfstoffe und Therapeutika", CHEManager (in German), retrieved November 11, 2020
  122. ^ High Tech Corporate Services GmbH - News: BioNTech schließt weltweite strategische Zusammenarbeit mit Genentech zur Entwicklung individualisierter mRNA-Krebstherapien (in German), retrieved November 11, 2020
  123. ^ Armin Huber (September 27, 2016), "BioNTech und Genentech kooperieren", finanzwelt (in German), retrieved November 11, 2020
  124. ^ BioNTech und Genevant Sciences vereinbaren strategische Partnerschaft mit mRNA-Fokus für seltene Erkrankungen (in German), retrieved November 11, 2020
  125. ^ Freshfields berät BioNTech bei Partnerschaft mit Genevant Sciences (in German), retrieved November 11, 2020
  126. ^ Pfizer und BioNTech entwickeln Impfstoffkandidaten gegen COVID-19 (in German), retrieved November 11, 2020
  127. ^ MIG Fonds, "Pfizer Inc. und MIG Fonds Portfoliounternehmen BioNTech denken über Erweiterung der Forschungskooperation für Corona-Impfstoff nach. (Press Release)", PresseBox (in German), retrieved November 11, 2020
  128. ^ Markus Schug, "Millionen-Dollar-Förderung: Geld von Bill Gates für Mainzer Forscher", Frankfurter Allgemeine Zeitung (in German), ISSN 0174-4909, retrieved November 11, 2020
  129. ^ „Die Kombination Deutschland-USA ist für BioNTech genau die richtige“ (in German), January 21, 2020, retrieved November 11, 2020
  130. ^ Gates-Stiftung investiert rund 50 Millionen Euro in Mainzer Unternehmen BioNtech (in German), November 11, 2020, retrieved November 11, 2020
  131. ^ "BioNTech und InstaDeep geben strategische Partnerschaft bekannt und gründen AI Innovation Lab zur Entwicklung neuer Immuntherapien.", boerse.de (in German), November 25, 2020, retrieved November 27, 2020
  132. ^ thomas, Das TRON gratuliert seinem Kooperationspartner BioNTech SE zum erfolgreichen Börsengang. (in German), TRON Translational Oncology Mainz, retrieved November 11, 2020
  133. ^ Erstes Beispiel eines klinisch anwendbaren und systemischen mRNA-Impfstoffs für die Krebsimmuntherapie vorgestellt (in German), retrieved November 11, 2020
  134. ^ Bundesministerium für Bildung und Forschung, Ci3: BioNTech schließt weltweite strategische Zusammenarbeit mit Genentech zur Entwicklung individualisierter mRNA-Krebstherapien (13. Oktober 2016) (in German), retrieved November 11, 2020
  135. ^ Richtfest Biotech-Campus Mainz (in German), retrieved November 11, 2020
  136. ^ Spitzencluster Ci3 mit personalisierten Krebsimpfstoffen europaweit führend | CHEManager (in German), retrieved November 11, 2020
  137. ^ Kooperationen | BioNTech (in German), Deutsches Zentrum für Infektionsforschung, retrieved November 11, 2020
  138. ^ Bundesministerium für Bildung und Forschung (BMBF), Coronavirus: Das ist der Stand bei der Impfstoff-Entwicklung. (in German), retrieved November 11, 2020
  139. ^ "Tumor Neoantigen Selection Alliance (TESLA)", Parker Institute for Cancer Immunotherapy, retrieved November 11, 2020
  140. ^ "BioNTech wird Teil von TESLA", Transkript (in German), Biocom, retrieved November 11, 2020
  141. ^ Siegfried Hoffmann, "Biotechnologie: Mit Impfstoffen gegen Infektionskrankheiten will BioNTech weiter expandieren.", Handelsblatt (in German), retrieved November 11, 2020
  142. ^ "BioNTech meldet IPO an Nasdaq an", Ärzte-Zeitung (in German), September 12, 2019, retrieved November 11, 2020
  143. ^ Intellectual Property, BioNTech SE, retrieved November 11, 2020
  144. ^ "BioNTech Patents", CB Insights, retrieved November 12, 2020
  145. ^ "Patents Assigned to BioNTech", Justia Patents Search, retrieved November 12, 2020
  146. ^ "BioNTech: Wie wirkt der mRNA-Impfstoff Kandidat?", patent-anmelden.net (in German), October 23, 2020, retrieved November 11, 2020
  147. ^ Jacek Jemielity, Joanna Kowalska, Edward Darżynkiewicz and team (Poland), European Patent Office (EPO), retrieved November 12, 2020
  148. ^ "Polski patent zarobił już 610 mln euro, ale... dla firmy z Niemiec. Pozbyliśmy się kury znoszącej złote jajka?", wyborcza.pl (in Polish), retrieved November 12, 2020
  149. ^ Cecilia Martin, Drew Lowery (July 27, 2020), "mRNA vaccines: intellectual property landscape", Nature Reviews Drug Discovery, vol. 19, no. 9, pp. 578–578, doi:10.1038/d41573-020-00119-8, retrieved November 12, 2020

External links[edit]


Retrieved from "https://en.wikipedia.org/w/index.php?title=User:J_at_BioNTech/sandbox/BioNTech&oldid=1039271531"